Cite
HARVARD Citation
Bendell, J. et al. (2017). A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer. Cancer investigation. pp. 386-392. [Online].